Today, PhRMA President and CEO John Castellani testified before the House Energy and Commerce subcommittee on Commerce, Manufacturing and Trade about an ambitious new free trade agreement being negotiated between the United States and the European Union.
This week, negotiators conclude the 18th round of Trans-Pacific Partnership (TPP) negotiations in Malaysia. The agreement, which includes Malaysia and 11 other nations, not only provides the United States with an entrée into the Asia Pacific region, but also opens new markets for all participating countries.
The United States faces a growing number of health care challenges.
Big storms – like Sandy, like Katrina – happen. The toll can be devastating. Proper preparation to meet the human, logistical and supply-chain problems that come along with a big storm is critical.
Last week’s ‘Conversations’ question “What steps should the U.S. take to protect and strengthen IP rights domestically and overseas?” prompted interesting responses from the U.S.
The biopharmaceutical community has made tremendous progress in recent years developing innovative treatments for chronic conditions, thanks to advancements in science and medicine. Not only do these advancements improve people’s lives every day, they also provide hope that we may one day be able to prevent or cure diseases like Alzheim
Today Show contributor Linda Carroll wrote a great article about the importance of detecting Alzheimer's disease earlier in life.
This week in Malaysia, the United States continues Trans-Pacific Partnership (TPP) negotiations with many of its most important Asia-Pacific trading partners. As we’ve discussed extensively on the Catalyst, through TPP the U.S.
I’m not talking about a broken heart from love, but rather from heart disease.
A chronic disease is detrimental to more than just the person who has it – its impact ripples through the health care system and economy as a whole. According to research by the Robert Wood Johnson Foundation, 80 cents of every dollar spent on health care in the United States goes to treat chronic disease.
The increasing burden of chronic diseases, as well as potential solutions to the problem, were a major focus for us this week.
From cancer and diabetes to heart disease and hypertension, prevalence of chronic disease in America has reached epidemic proportions. In the U.S., 75 percent of our health care dollars go toward its treatment.
It was one year ago today that the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law, reauthorizing the Prescription Drug User Fee Act (
Every day, our industry works to develop new medicines that extend and improve the quality of life for patients. As the Baby Boom generation enters retirement age, one critical health care issue that we must address is how to keep our nation’s seniors healthy. It’s a topic that I come across regularly in my role at PhRMA.
Research shows that properly adhering to medications is a major challenge, but patients who take their medications as prescribed are more likely to have better outcomes.
According to new research by Milliman, a leading actuarial consulting firm, only about 3.3 percent of Part D enrollees filled a prescription for at least one specialty drug in 2011, a very small portion of total Part D enrollme
In the future, we just might be able to control non-communicable diseases with our phones.
We all know someone impacted by heart disease or stroke. Well that applies to the researchers working on medicines to combat these deadly diseases, as well. Not surprising when you consider that heart disease is the leading cause of death for both men and women, with someone dying from a heart disease related event every minute.
As we continue to explore health policy through our ‘Conversations’ forum, today we’re introducing the next question and encourage you to weigh in with your thoughts:
As a recent update on implementation of the Prescription Drug User Fee Act (PDUFA) explained, a new review program for new molecular entity (NME) new drug applications (NDA) and original biologic license applications (BLA) was established under